



Julie Dixon

Head, Global Regulatory Affairs
Oncology Business Unit

Julie Dixon is the Head of Global Regulatory Affairs for the Oncology Business Unit. Julie joined Takeda in January 2021 and will partner with the teams to develop and execute innovative regulatory strategies to ensure the provision of life-changing therapies for patients.

Based in Cambridge, MA, Julie brings more than 20 years of pharmaceutical experience, encompassing drug discovery experience through integrating regulatory strategy into drug development and precision medicine. Prior to joining Takeda, Julie served as Global Regulatory Head of the Cardiovascular Therapeutic Area at Bristol-Myers Squibb (BMS). Prior to this and for the previous 14 years, Julie's main focus was in the oncology area where she made significant contributions to programs in all stages of development, including the initial FDA approval for Empliciti™. Having led the GRA early oncology team at BMS, Julie has extensive experience of driving innovative regulatory approaches including the first uses of master protocols and platform trials. In addition, Julie led a team responsible for providing strategic guidance and oversight for the development and execution of global precision medicine regulatory strategies across therapeutic areas, including the development of complementary and companion diagnostics. She has been active in the oncology community, having represented BMS in industry groups such as PhRMA, BIO, and Friends of Cancer Research (FOCR), and has presented at key conferences including FOCR, ECCO, Biomarkers & Diagnostics World Congress, and World CDx. Prior to joining BMS, Julie held both research and regulatory strategy positions at Bayer HealthCare Pharmaceuticals. She was a global regulatory lead in the areas of cardiovascular and diagnostic imaging and was a medicinal chemist and project leader responsible for oncology research programs.

Julie holds a Ph.D. in Synthetic Organic Chemistry from the University of Illinois, Urbana/Champaign, and conducted post-doctoral research studies at Yale University. She also holds a BS in Chemistry from the University of Michigan.



ONCOLOGY